Luye Pharma Group (02186.HK) reported its financial results for 2019 on March 27, 2020. According to the results, the company has achieved a total revenue of RMB 6.358 billion, up 22.9% year-on-year. EBITDA was RMB 2.488 billion, up 26.9% year-on-year; and normalized profit attributed to shareholders was RMB 1.592 billion, up 19.4% year-on-year.
Over the past year, Luye Pharma has achieved remarkable progress in R&D, marketing, business development and collaboration by resolutely carrying out its corporate strategies. The company is also actively transforming itself to lay a solid foundation for the sustainable growth in the future. Financial highlights of 2019 are as follows:
